Abeona Therapeutics
Tracked across 2 events · 14 articles · First seen Apr 02, 2026 · Last active Apr 07, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Abeona Therapeutics Inc. appointed Keith A. Goldan to its Board of Directors and as Chairman of its Audit Committee, aiming to strengthen its leadership and advance strategic and financial objectives. This move is expected to support the company's growth as a commercial-stage biotech company, especially with the commercial momentum building for its first US launch of ZEVASKYN.
Apr 07, 2026 · 7 articles
Regulatory
Abeona Therapeutics originally developed UX111 before transferring it to Ultragenyx for further development. This event highlights Abeona Therapeutics' contribution to the therapy's early stages.
Apr 02, 2026 · 7 articles
100
Abeona Therapeutics appointed new independent board member and Audit Committee Chairman Keith A. GoldanAbeona Therapeutics...
100
Keith A. Goldan joined Board of Directors and became Audit Committee Chairman Abeona TherapeuticsAbeona Therapeutics...
Keith A. Goldan
Board Member
↔
Abeona Therapeutics
Keith A. Goldan is an independent member of the Board of Directors of Abeona The
Michael Amoroso
Chairman of Board of Directors
↔
Abeona Therapeutics
Michael Amoroso is the Chairman of the Board of Directors of Abeona Therapeutics
NEWSDESK
Track Abeona Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard